Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Hold" by Brokerages

Key Points

• Cardiff Oncology has an average “Hold” rating from seven analysts: four holds, two buys and one sell. The average 12-month price target is $7.50.
• CRDF shares rose 16% to $1.02, while trading near the lower end of their 52-week range of $0.76 to $3.31. The stock has a market capitalization of approximately $79.4 million.
• The company reported a quarterly loss of $0.14 per share, missing the $0.12 consensus estimate, although revenue of $0.10 million exceeded expectations. Director Gary Pace and CEO Mani Mohindru also purchased company shares in June.

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been given an average rating of "Hold" by the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $7.50.

Several brokerages have issued reports on CRDF. William Blair cut Cardiff Oncology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, August 11th. Wall Street Zen lowered Cardiff Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. TD Cowen cut Cardiff Oncology from a "buy" rating to a "hold" rating in a research note on Monday, June 1st. HC Wainwright downgraded Cardiff Oncology from a "buy" rating to a "neutral" rating in a research report on Monday, June 1st. Finally, Craig Hallum lowered Cardiff Oncology from a "buy" rating to a "hold" rating and set a $2.00 target price on the stock. in a research note on Wednesday, June 3rd.

Cardiff Oncology Stock Up 16.0%

NASDAQ:CRDF traded up $0.14 during mid-day trading on Monday, hitting $1.02. 667,034 shares of the stock traded hands, compared to its average volume of 1,177,771. Cardiff Oncology has a 52 week low of $0.76 and a 52 week high of $3.31. The stock has a market capitalization of $79.43 million, a price-to-earnings ratio of -1.70 and a beta of 1.49. The firm's 50 day moving average is $1.07 and its two-hundred day moving average is $1.48.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.The business had revenue of $0.10 million during the quarter, compared to analysts' expectations of $0.06 million. As a group, research analysts predict that Cardiff Oncology will post -0.63 EPS for the current year.

Insiders Place Their Bets

In related news, Director Gary W. Pace purchased 30,000 shares of the business's stock in a transaction on Thursday, June 18th. The shares were acquired at an average price of $1.22 per share, for a total transaction of $36,600.00. Following the purchase, the director owned 1,356,376 shares of the company's stock, valued at $1,654,778.72. This trade represents a 2.26% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mani Mohindru bought 24,703 shares of the business's stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average cost of $1.21 per share, for a total transaction of $29,890.63. Following the completion of the transaction, the chief executive officer owned 24,703 shares in the company, valued at $29,890.63. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 8.50% of the company's stock.

Institutional Trading of Cardiff Oncology

Large investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in shares of Cardiff Oncology during the second quarter worth about $37,000. Glenview Trust Co acquired a new position in Cardiff Oncology in the 2nd quarter worth approximately $56,000. Capstone Investment Advisors LLC acquired a new position in Cardiff Oncology in the 2nd quarter worth approximately $67,000. X Square Capital LLC purchased a new position in Cardiff Oncology during the 2nd quarter worth approximately $267,000. Finally, Ieq Capital LLC acquired a new stake in Cardiff Oncology during the 2nd quarter valued at approximately $58,000. Hedge funds and other institutional investors own 16.29% of the company's stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff's pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source